Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how BARDA contracts affect Emergent BioSolutions’ cash flow can feel like hunting for anthrax spores in a 300-page 10-K. Footnotes on NARCAN sales, vaccine stockpile renewals, and facility inspections are scattered across multiple exhibits, making even seasoned analysts scroll endlessly. This page is where you’ll find Emergent BioSolutions SEC filings explained simply, without missing a single nuance.
Stock Titan solves that problem with AI-powered summaries that translate every filing into plain English. When an Emergent BioSolutions quarterly earnings report 10-Q filing hits EDGAR, our engine highlights year-over-year commercial-segment trends in minutes. Need to spot an Emergent BioSolutions 8-K material events explained? You’ll receive a real-time alert the moment it’s posted.
- Instant view of Emergent BioSolutions insider trading Form 4 transactions
- Emergent BioSolutions Form 4 insider transactions real-time push notifications for executive stock moves
- Emergent BioSolutions annual report 10-K simplified with section-by-section AI notes
- Clear Emergent BioSolutions proxy statement executive compensation breakdowns
- Actionable Emergent BioSolutions earnings report filing analysis each quarter
These tools help you compare manufacturing capacity disclosures across sites, verify government contract backlogs, and monitor Emergent BioSolutions executive stock transactions Form 4 before making portfolio decisions. Whether you’re understanding Emergent BioSolutions SEC documents with AI or exporting tables for a model, Stock Titan keeps every detail one click away—no more wading through dense biotech jargon.
Emergent BioSolutions has secured a significant contract modification worth $62.4 million from the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services. The contract relates to the company's BAT® (Botulism Antitoxin Heptavalent) product.
Key details of the announcement:
- The modification is part of an existing 10-year contract (75A50119C00075) with ASPR
- BAT® is used to treat symptomatic botulism following exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G
- The treatment is approved for both adult and pediatric patients
- The filing was signed by Richard S. Lindahl, Executive Vice President, CFO and Treasurer
This contract modification represents a significant government commitment to maintaining strategic preparedness against botulism threats and demonstrates continued confidence in Emergent's biodefense capabilities.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
What is the primary mission of Emergent BioSolutions?
How does Emergent BioSolutions generate its revenue?
What types of products does Emergent BioSolutions offer?
How does the company support public health and emergency preparedness?
What are the main business segments of Emergent BioSolutions?
In which industries does Emergent operate?
How does Emergent BioSolutions ensure the safety and efficacy of its products?
What role do government contracts play in Emergent's business model?
